

Application No.: 09/685,189

Page 2

B1  
Part C7

LEACV-X<sub>101</sub>-Q-X<sub>103</sub>-V-X<sub>105</sub>-X<sub>106</sub>-X<sub>107</sub>-X<sub>108</sub>-TPLMN-X<sub>114</sub>-D-X<sub>116</sub>-ILAV-X<sub>121</sub>-KY-X<sub>124</sub>-QRITLYL-X<sub>132</sub>-E-X<sub>134</sub>-KYSPC-X<sub>140</sub>-WEVVRAEIMRSFSF\$TNLQKRLRRKE, or a conservatively substituted variation thereof;

wherein X<sub>11</sub> is N or D; X<sub>12</sub> is R, S, or K; X<sub>15</sub> is L or M; X<sub>16</sub> is I, M, or V; X<sub>19</sub> is A or G; X<sub>22</sub> is G or R; X<sub>24</sub> is I or T; X<sub>26</sub> is P or H; X<sub>34</sub> is H, Y or Q; X<sub>38</sub> is F or L; X<sub>40</sub> is Q or R; X<sub>45</sub> is G or S; X<sub>46</sub> is N or H; X<sub>47</sub> is Q or R; X<sub>50</sub> is K or R; X<sub>51</sub> is A or T; X<sub>55</sub> is S or F; X<sub>56</sub> is V or A; X<sub>57</sub> is L or F; X<sub>60</sub> is M or I; X<sub>61</sub> is I or M; X<sub>67</sub> is L or F; X<sub>72</sub> is D or N; X<sub>75</sub> is A or V; X<sub>76</sub> is A or T; X<sub>78</sub> is E or D; X<sub>79</sub> is Q or E; X<sub>80</sub> is S, R, T, or N; X<sub>83</sub> is E or D; X<sub>85</sub> is F or L; X<sub>88</sub> is E or G; X<sub>90</sub> is Y, H, N; X<sub>95</sub> is D, E, or N; X<sub>101</sub> is I, M, or V; X<sub>103</sub> is E or G; X<sub>105</sub> is G or W; X<sub>106</sub> is V or M; X<sub>107</sub> is E, G, or K; X<sub>108</sub> is E or G; X<sub>114</sub> is V, E, or G; X<sub>116</sub> is S or P; X<sub>121</sub> is K or R; X<sub>124</sub> is F or L; X<sub>132</sub> is T, I, or M; X<sub>134</sub> is K or R; and X<sub>140</sub> is A or S.

Concluded

B2

36. (Amended) The polypeptide of claim 34, comprising a sequence selected from the group consisting of SEQ ID NO:36 to SEQ ID NO:46 and SEQ ID NO:48 to SEQ ID NO:54.

Please add the following new claims:

149. (New) An isolated or recombinant polypeptide comprising a sequence having at least 96% sequence identity over the entire length of a sequence selected from the group consisting of: SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:45, SEQ ID NO:52, SEQ ID NO:54, and a fragment thereof which exhibits an antiproliferative activity in a human Daudi cell line-based cell proliferation assay or an antiviral activity in a human WISH cell/EMCV-based assay.

150. (New) The polypeptide of claim 149, comprising a sequence having at least 96% sequence identity over the entire length of SEQ ID NO:40 or a fragment thereof which exhibits an antiproliferative activity in a human Daudi cell line-based cell proliferation assay or an antiviral activity in a human WISH cell/EMCV-based assay.

151. (New) The polypeptide of claim 150, comprising a sequence selected from the group consisting of SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:46, and a fragment thereof which

Application No.: 09/685,189  
Page 3

exhibits an antiproliferative activity in a human Daudi cell line-based cell proliferation assay or an antiviral activity in a human WISH cell/EMCV-based assay.

152. (New) The polypeptide of claim 149, comprising a sequence having at least 96% sequence identity over the entire length of SEQ ID NO:41 or a fragment thereof which exhibits an antiproliferative activity in a human Daudi cell line-based cell proliferation assay or an antiviral activity in a human WISH cell/EMCV-based assay.

153. (New) The polypeptide of claim 152, comprising a sequence selected from the group consisting of SEQ ID NO:41, SEQ ID NO:40, SEQ ID NO:46, SEQ ID NO:39, SEQ ID NO:45, SEQ ID NO:36, and a fragment thereof which exhibits an antiproliferative activity in a human Daudi cell line-based cell proliferation assay or an antiviral activity in a human WISH cell/EMCV-based assay.

154. (New) The polypeptide of claim 149, comprising a sequence having at least 96% sequence identity over the entire length of SEQ ID NO:45 or a fragment thereof which exhibits an antiproliferative activity in a human Daudi cell line-based cell proliferation assay or an antiviral activity in a human WISH cell/EMCV-based assay.

155. (New) The polypeptide of claim 154, comprising a sequence selected from the group consisting of SEQ ID NO:45, SEQ ID NO:36, SEQ ID NO:46, SEQ ID NO:41, SEQ ID NO:39, SEQ ID NO:42, and a fragment thereof which exhibits an antiproliferative activity in a human Daudi cell line-based cell proliferation assay or an antiviral activity in a human WISH cell/EMCV-based assay.

156. (New) The polypeptide of claim 149, comprising a sequence having at least 97% sequence identity over the entire length of a sequence selected from the group consisting of: SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:45, SEQ ID NO:52, SEQ ID NO:54, and a fragment thereof which exhibits an antiproliferative activity in a human Daudi cell line-based cell proliferation assay or an antiviral activity in a human WISH cell/EMCV-based assay.